| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
4,933 |
4,366 |
$636K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
1,366 |
1,210 |
$295K |
| 80053 |
Comprehensive metabolic panel |
4,573 |
3,970 |
$207K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
503 |
408 |
$181K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
4,589 |
3,902 |
$109K |
| 36415 |
Collection of venous blood by venipuncture |
5,936 |
5,038 |
$41K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
618 |
531 |
$33K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
112 |
107 |
$24K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
217 |
180 |
$13K |
| 0240U |
|
63 |
58 |
$12K |
| 84443 |
Thyroid stimulating hormone (TSH) |
241 |
237 |
$12K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
126 |
79 |
$11K |
| A4217 |
Sterile water/saline, 500 ml |
322 |
234 |
$10K |
| 84484 |
|
238 |
190 |
$9K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
170 |
145 |
$8K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
255 |
240 |
$8K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
209 |
180 |
$8K |
| 84439 |
|
167 |
163 |
$6K |
| 87070 |
|
127 |
113 |
$5K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
89 |
84 |
$4K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
268 |
264 |
$4K |
| 71045 |
Radiologic examination, chest; single view |
73 |
67 |
$4K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
197 |
189 |
$3K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
130 |
113 |
$2K |
| 80061 |
Lipid panel |
50 |
49 |
$2K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
33 |
25 |
$2K |
| 87430 |
|
90 |
88 |
$2K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
71 |
65 |
$2K |
| 81001 |
|
105 |
96 |
$1K |
| 80306 |
|
18 |
17 |
$1K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
73 |
68 |
$1K |
| 71046 |
Radiologic examination, chest; 2 views |
13 |
12 |
$1K |
| 82553 |
|
26 |
25 |
$1K |
| 87641 |
|
17 |
16 |
$857.82 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
16 |
15 |
$848.65 |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
16 |
16 |
$819.45 |
| 81003 |
|
102 |
80 |
$795.90 |
| 83690 |
|
28 |
24 |
$788.13 |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
41 |
39 |
$652.52 |
| 82550 |
|
26 |
25 |
$590.83 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
30 |
15 |
$381.94 |
| 87081 |
|
26 |
25 |
$338.93 |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
15 |
12 |
$308.20 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
38 |
37 |
$300.82 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
13 |
13 |
$293.19 |
| 87420 |
|
13 |
12 |
$184.42 |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
14 |
14 |
$120.48 |
| 82565 |
|
13 |
12 |
$65.97 |
| 84132 |
|
13 |
12 |
$60.29 |
| 84295 |
|
13 |
12 |
$57.75 |
| 84520 |
|
13 |
12 |
$56.34 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
14 |
13 |
$55.52 |